BRAIN Biotech AG reports record figures in fiscal year 2021/22
Despite a challenging geopolitical environment, BRAIN Biotech announce strong sales laying the foundations for ongoing future dynamic growth.
Leading provider of biotechnology solutions and parent company of the BRAIN Group, BRAIN Biotech AG today announce record figures presented in its Annual Report for financial year 2021/22. The year saw strong organic growth in both the BioScience and BioIndustrial business segments delivering increased profitability across the Group.
Highlights from Fiscal Year 2021/22:
- Group sales grew by 29 %
- Total operating performance exceeds for the first time 50 million euros
- Both business segments with strong growth and increasing profitability in the past fiscal year
- Foundations laid for ongoing future dynamic growth
“The 2021/22 financial year was characterized by various geopolitical crises and the continuing effects of the pandemic situation. Nevertheless, and as planned, we were able to continue to significantly expand our product business, particularly in enzymes, and revive our project business in the Tailor-Made Solutions area to the pre-crisis level.
